Neurogene Inc. (NGNE) Form 8-K — Nov 9, 2026
Neurogene reported Q3 2026 results with a net loss of $29.0 million and $359.7 million in cash, providing runway into the first quarter of 2029 — funding operations through the Embolden data readout and planned BLA submission for NGN-401. The lead gene therapy NGN-401 for Rett syndrome remains on track: PPQ runs to support the BLA are expected to complete by year-end 2026, and topline data from the Embolden registrational trial (25 participants fully dosed) are anticipated in the second half of 2027.
Key figures
- Revenue
- 0
- Cash Position
- 359700000
- Cash runway
- into Q1 2029
- Net loss q3 2025
- 21000000
- G a expense q3 2025
- 6600000
- G a expense q3 2026
- 8900000
- R d expense q3 2025
- 17200000
- R d expense q3 2026
- 23500000
- Total safety database n
- 35
- Embolden success threshold
- 36% (9 of 25)
- Embolden participants dosed
- 25
- Phase12 composite responder rate
- 80% (8 of 10)
- Average milestones per participant at 12plus months
- 4.7
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.